MedTrace Logo

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

NCT04989803 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 247

Last updated 2026-04-24

No results posted yet for this study

Summary

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

Conditions

  • Relapsed and/or Refractory B-cell Lymphoma

Interventions

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy administered intravenously

DRUG

Fludarabine

Lymphodepleting chemotherapy administered intravenously

BIOLOGICAL

KITE-363

A single infusion of CAR-transduced autologous T cells administered intravenously

BIOLOGICAL

KITE-753

A single infusion of CAR-transduced autologous T cells administered intravenously

Sponsors & Collaborators

  • Kite, A Gilead Company

    lead INDUSTRY

Principal Investigators

  • Kite Study Director · Kite, A Gilead Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2030-02-28
Completion
2030-02-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04989803 on ClinicalTrials.gov